LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Lista de Ações・Guardant Health Inc

Guardant Health Inc

Fechado

SetorSaúde

126.95 -2.27

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

125.2

Máximo

129.77

Indicadores-chave
By Trading Economics
Rendimento	16M -112M
Vendas	20M 302M
EPS	-0.45
Margem de lucro	-37.152
Funcionários	2,490
EBITDA	18M -101M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+5.2% upside

Dividendos
By Dow Jones
Próximos Ganhos	29 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	5B 17B
Abertura anterior	129.22
Fecho anterior	126.95

Sentimento de Notícias

By Acuity

50%

154 / 344 Ranking em Healthcare

Guardant Health Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de jun. de 2026, 23:22 UTC

Ganhos

Grandes Movimentos do Mercado

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 de jun. de 2026, 23:09 UTC

Ações em Alta

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 de jun. de 2026, 20:51 UTC

Ganhos

Costco Reports 15% Sales Growth in May

3 de jun. de 2026, 20:43 UTC

Ganhos

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 de jun. de 2026, 23:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 de jun. de 2026, 23:15 UTC

Conversa de Mercado

Ganhos

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 de jun. de 2026, 22:08 UTC

Ações em Alta

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 de jun. de 2026, 21:54 UTC

Conversa de Mercado

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 de jun. de 2026, 21:18 UTC

Ganhos

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 de jun. de 2026, 21:15 UTC

Ganhos

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 de jun. de 2026, 21:13 UTC

Ganhos

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 de jun. de 2026, 21:12 UTC

Ganhos

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 de jun. de 2026, 21:09 UTC

Ganhos

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 de jun. de 2026, 21:03 UTC

Ganhos

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de jun. de 2026, 20:43 UTC

Ganhos

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 de jun. de 2026, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 de jun. de 2026, 20:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 de jun. de 2026, 20:35 UTC

Ganhos

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 de jun. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 de jun. de 2026, 20:17 UTC

Ganhos

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 de jun. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Adj EPS $2.44 >AVGO

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q EPS $1.91 >AVGO

3 de jun. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

3 de jun. de 2026, 20:15 UTC

Ganhos

Broadcom 2Q Rev $22.19B >AVGO

Comparação entre Pares

Variação de preço

Guardant Health Inc Previsão

Preço-alvo

By TipRanks

5.2% parte superior

Previsão para 12 meses

Média 136.94 USD 5.2%

Máximo 160 USD

Mínimo 120 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Guardant Health Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

17 ratings

Comprar

Manter

Vender

Com base em 17 analistas que deram avaliações de ações para Guardant Health Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

154 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.